Ito Yasuhiro, Yoshida Hiroshi, Uruno Takashi, Takamura Yuuki, Miya Akihiro, Kuma Kanji, Miyauchi Akira
Department of Surgery, Kuma Hospital, 8-2-35, Shimoyamate-Dori, Chuo-ku, Kobe City, 650-0011, Japan.
Breast Cancer. 2004;11(3):295-300. doi: 10.1007/BF02984552.
Previous studies have indicated that cdc25B and cdc25A phosphatase stimulate cell cycle progression and also play a role in malignant transformation of cells. In this study, we investigated the expression of these phosphatases in breast carcinoma to elucidate their significance.
We immunohistochemically examined cdc25B and cdc25A expression in 46 cases of breast carcinoma.
Cdc25B and cdc25A were negative or only equivocally expressed in glandular epithelial cells. In breast carcinoma, 56.5% of cases had high levels of cdc25B expression. Interestingly, the expression of cdc25B was significantly lower in cases with biologically aggressive phenotypes. The cdc25A level was high in 69.6% of cases, but we could not find any relationship between cdc25A expression and clinicopathological parameters.
These results suggest that cdc25B is important especially in the early phase of breast carcinoma progression.
先前的研究表明，细胞分裂周期蛋白25B（cdc25B）和细胞分裂周期蛋白25A（cdc25A）磷酸酶可刺激细胞周期进程，并且在细胞的恶性转化中也发挥作用。在本研究中，我们调查了这些磷酸酶在乳腺癌中的表达情况，以阐明它们的意义。
我们采用免疫组织化学方法检测了46例乳腺癌中cdc25B和cdc25A的表达。
cdc25B和cdc25A在腺上皮细胞中呈阴性或仅为可疑表达。在乳腺癌中，56.5%的病例cdc25B表达水平较高。有趣的是，在具有生物学侵袭性表型的病例中，cdc25B的表达明显较低。69.6%的病例cdc25A水平较高，但我们未发现cdc25A表达与临床病理参数之间存在任何关联。
这些结果表明，cdc25B在乳腺癌进展的早期阶段尤其重要。
